MindMed to Present at Upcoming April Medical Conferences
April 02 2024 - 7:00AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe
Canada: MMED), (the “Company” or “MindMed”), a clinical stage
biopharmaceutical company developing novel product candidates to
treat brain health disorders, announced today that it will present
posters describing the impact that COVID has had on the
epidemiology of Generalized Anxiety Disorder at two upcoming
medical conferences:
European Psychiatric Association (EPA)
2024 Congress Title: Prevalence of Generalized
Anxiety Disorder Among Five European Countries Before and During
COVID Format: Poster Presenter: Phong Duong, PharmD
Date and Time: Tuesday, April 9, 2024, at 9:30 AM
Location: Budapest, Hungary
Anxiety & Depression Association of
America (ADAA) 2024 Conference Title: U.S.
Generalized Anxiety Disorder Related To COVID-19 Pandemic
Population by Age and Gender Format: Poster
Presenter: Phong Duong, PharmD Date and Time: Friday,
April 12, 2024, at 5:00 PM Location: Boston, MA
Posters will be available on MindMed’s Company website following
the conferences.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the Cboe
Canada (formerly known as the NEO Exchange, Inc.) under the symbol
MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding anticipated
upcoming presentations; and the potential benefits of the Company’s
product candidates. There are numerous risks and uncertainties that
could cause actual results and the Company’s plans and objectives
to differ materially from those expressed in the forward-looking
information, including history of negative cash flows; limited
operating history; incurrence of future losses; availability of
additional capital; lack of product revenue; compliance with laws
and regulations; difficulty associated with research and
development; risks associated with clinical trials or studies;
heightened regulatory scrutiny; early stage product development;
clinical trial risks; regulatory approval processes; novelty of the
psychedelic inspired medicines industry; as well as those risk
factors discussed or referred to herein and the risks described in
the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023, under headings such as “Special Note Regarding
Forward-Looking Statements,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations,” and other filings and furnishings made by the Company
with the securities regulatory authorities in all provinces and
territories of Canada which are available under the Company’s
profile on SEDAR+ at www.sedarplus.ca
and with the U.S. Securities and Exchange Commission on EDGAR at
www.sec.gov. Except as required by
law, the Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402337045/en/
For Media: media@mindmed.co For investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Aug 2023 to Aug 2024